Idrofos Kit is a combination pharmaceutical formulation containing Ibandronic Acid 150 mg, Calcium 225 mg, and Vitamin D3 800 IU, designed to support bone health and treat conditions associated with bone loss. Ibandronic Acid, a bisphosphonate, acts by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing the risk of fractures in patients with osteoporosis or other metabolic bone diseases. The inclusion of Calcium is essential for maintaining adequate serum calcium levels, which is critical for bone mineralization and overall skeletal integrity. Vitamin D3 facilitates intestinal absorption of calcium and phosphate, promoting effective bone formation and remodeling. Idrofos Kit is indicated for the treatment and prevention of osteoporosis in postmenopausal women and other patients at high risk of fractures, as well as for managing bone metastases in certain malignancies. The combined action of these components ensures a comprehensive approach to bone health by addressing both the resorptive and formative aspects of bone metabolism. Administration should follow medical guidance, with attention to renal function and potential contraindications such as hypocalcemia or hypersensitivity. Regular monitoring of calcium levels and adherence to dosing schedules are recommended to optimize therapeutic outcomes and minimize adverse effects.